CN105793257B - 苯并咪唑环化合物的晶形及其用途 - Google Patents

苯并咪唑环化合物的晶形及其用途 Download PDF

Info

Publication number
CN105793257B
CN105793257B CN201480065274.7A CN201480065274A CN105793257B CN 105793257 B CN105793257 B CN 105793257B CN 201480065274 A CN201480065274 A CN 201480065274A CN 105793257 B CN105793257 B CN 105793257B
Authority
CN
China
Prior art keywords
compound
disorders
methyl
chloro
benzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480065274.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN105793257A (zh
Inventor
克里斯托弗·博斯
克莉丝汀·普罗奇
马库斯·古德
比比亚·海德曼
蒂埃里·西弗朗
马库斯·冯劳默尔
约迪·T·威廉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aidu West Pharmaceutical Co Ltd
Original Assignee
Aidu West Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aidu West Pharmaceutical Co Ltd filed Critical Aidu West Pharmaceutical Co Ltd
Publication of CN105793257A publication Critical patent/CN105793257A/zh
Application granted granted Critical
Publication of CN105793257B publication Critical patent/CN105793257B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201480065274.7A 2013-12-03 2014-12-02 苯并咪唑环化合物的晶形及其用途 Active CN105793257B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2013060596 2013-12-03
IBPCT/IB2013/060596 2013-12-03
PCT/IB2014/066508 WO2015083070A1 (en) 2013-12-03 2014-12-02 Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists

Publications (2)

Publication Number Publication Date
CN105793257A CN105793257A (zh) 2016-07-20
CN105793257B true CN105793257B (zh) 2018-11-13

Family

ID=52282786

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480065274.7A Active CN105793257B (zh) 2013-12-03 2014-12-02 苯并咪唑环化合物的晶形及其用途

Country Status (31)

Country Link
US (1) US9914720B2 (enExample)
EP (1) EP3077389B1 (enExample)
JP (1) JP6496733B2 (enExample)
KR (1) KR102361418B1 (enExample)
CN (1) CN105793257B (enExample)
AU (1) AU2014358742B2 (enExample)
CA (1) CA2929423C (enExample)
CL (1) CL2016001342A1 (enExample)
CY (1) CY1119695T1 (enExample)
DK (1) DK3077389T3 (enExample)
EA (1) EA030137B1 (enExample)
ES (1) ES2651475T3 (enExample)
HK (1) HK1225731B (enExample)
HR (1) HRP20171773T1 (enExample)
HU (1) HUE035731T2 (enExample)
IL (1) IL245923B (enExample)
LT (1) LT3077389T (enExample)
MA (1) MA39163B1 (enExample)
MX (1) MX364208B (enExample)
MY (1) MY179862A (enExample)
NO (1) NO3077389T3 (enExample)
NZ (1) NZ721438A (enExample)
PH (1) PH12016500988B1 (enExample)
PL (1) PL3077389T3 (enExample)
PT (1) PT3077389T (enExample)
SA (1) SA516371231B1 (enExample)
SI (1) SI3077389T1 (enExample)
TW (1) TWI664177B (enExample)
UA (1) UA119549C2 (enExample)
WO (1) WO2015083070A1 (enExample)
ZA (1) ZA201604499B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101995683B1 (ko) 2012-06-04 2019-07-02 이도르시아 파마슈티컬스 리미티드 벤즈이미다졸-프롤린 유도체
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
UA116053C2 (uk) 2013-12-04 2018-01-25 Ідорсія Фармасьютікалз Лтд Застосування похідних бензоімідазолу-проліну
HRP20211304T1 (hr) 2017-05-03 2021-11-12 Idorsia Pharmaceuticals Ltd Pripravljanje derivata 2-([1,2,3]triazol-2-il)-benzojeve kiseline
PH12022552763A1 (en) 2020-04-19 2024-03-25 Idorsia Pharmaceuticals Ltd Medical use of daridorexant
BR112023015463A2 (pt) * 2021-02-02 2023-10-10 Medshine Discovery Inc Composto tetrahidropirrolocíclico e aplicação do mesmo
CN115925699B (zh) * 2022-02-25 2023-10-03 南京知和医药科技有限公司 具有镇痛活性的稠环化合物及其制备方法与用途
ES3038762A1 (es) 2024-04-12 2025-10-14 Moehs Iberica Sl Procedimiento de síntesis de ácido 5-metoxi-2-(2H-1,2,3-triazol-2yl)benzoico, sal sódica de dicho ácido como intermedio de síntesis y uso del ácido o de su sal en la preparación de daridorexant y ciertos intermedios en la síntesis del mismo

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1549816A (zh) * 2001-06-28 2004-11-24 ʷ 作为阿立新受体拮抗药的n-芳酰基环胺衍生物
WO2007135527A2 (en) * 2006-05-23 2007-11-29 Pfizer Products Inc. Benzimidazolyl compounds
CN102325770A (zh) * 2008-12-23 2012-01-18 葛兰素集团有限公司 用作食欲肽拮抗剂的哌啶衍生物

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282927A (en) 1964-05-21 1966-11-01 Bristol Myers Co 5-phenyl-4-thiazolylpenicillins
WO2001096302A1 (en) 2000-06-16 2001-12-20 Smithkline Beecham P.L.C. Piperidines for use as orexin receptor antagonists
US20030055037A1 (en) 2000-10-06 2003-03-20 Delombaert Stephane Benzimidazole and indole derivatives as CRF receptor modulators
ATE286897T1 (de) 2000-11-28 2005-01-15 Smithkline Beecham Plc Morpholinderivate als antagonisten an orexinrezeptoren
CA2446396A1 (en) 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. N-aroyl cyclic amines
EP1435955A2 (en) 2001-05-05 2004-07-14 SmithKline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
JP2006504695A (ja) 2002-09-18 2006-02-09 グラクソ　グループ　リミテッド オレキシン受容体アンタゴニストとしてのｎ−アロイル環状アミン
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225884D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
BRPI0508263B8 (pt) 2004-03-01 2021-05-25 Idorsia Pharmaceuticals Ltd derivados de 1, 2, 3, 4-tetra-hidro-isoquinolina, composição farmacêutica, e, uso de derivado de 1, 2, 3, 4-tetra-hidro-isoquinolina
JP4582722B2 (ja) 2006-03-15 2010-11-17 アクテリオン ファーマシューティカルズ リミテッド 記憶機能を向上させるテトラヒドロイソキノリン誘導体
JP2010500401A (ja) 2006-08-15 2010-01-07 アクテリオン ファーマシューティカルズ リミテッド アゼチジン化合物
WO2008038251A2 (en) 2006-09-29 2008-04-03 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.1.0]hexane derivatives
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
CL2007003827A1 (es) 2006-12-28 2008-09-26 Actelion Pharmaceuticals Ltd Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras.
WO2008087611A2 (en) 2007-01-19 2008-07-24 Actelion Pharmaceuticals Ltd Pyrrolidine- and piperidine- bis-amide derivatives
CL2008000836A1 (es) 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
WO2008139416A1 (en) 2007-05-14 2008-11-20 Actelion Pharmaceuticals Ltd 2-cyclopropyl-thiazole derivatives
US8030495B2 (en) 2007-05-23 2011-10-04 Coleman Paul J Cyclopropyl pyrrolidine orexin receptor antagonists
GB0712888D0 (en) 2007-07-03 2007-08-15 Glaxo Group Ltd Novel compounds
BRPI0813218A2 (pt) 2007-07-03 2014-12-23 Actelion Pharmaceuticals Ltd Composto, composição farmacêutica que o contém como princípio ativo e uso do composto.
WO2009003993A1 (en) 2007-07-03 2009-01-08 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
KR20100046047A (ko) 2007-07-27 2010-05-04 액테리온 파마슈티칼 리미티드 2-아자-비시클로[3.3.0]옥탄 유도체
CN101790515A (zh) 2007-07-27 2010-07-28 埃科特莱茵药品有限公司 反式-3-氮杂-双环[3.1.0]己烷衍生物
WO2009040730A2 (en) 2007-09-24 2009-04-02 Actelion Pharmaceuticals Ltd Pyrrolidines and piperidines as orexin receptor antagonists
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
EP2247586B1 (en) 2008-02-21 2012-04-25 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo[2.2.1]heptane derivatives
GB0806536D0 (en) 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds
WO2010004507A1 (en) 2008-07-07 2010-01-14 Actelion Pharmaceuticals Ltd Thiazolidine compounds as orexin receptor antagonists
WO2010038200A1 (en) 2008-10-01 2010-04-08 Actelion Pharmaceuticals Ltd Oxazolidine compounds as orexin receptor antagonists
EP2358711A1 (en) 2008-11-26 2011-08-24 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
JP2012509912A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
WO2010060471A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
EP2370427A1 (en) 2008-12-02 2011-10-05 Glaxo Group Limited N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives and uses thereof
US20100144760A1 (en) 2008-12-02 2010-06-10 Giuseppe Alvaro Novel compounds
KR20120007061A (ko) 2009-04-24 2012-01-19 글락소 그룹 리미티드 오렉신 길항제로서 사용되는 3-아자비시클로［4.1.0］헵탄
TW201209037A (en) 2010-08-24 2012-03-01 Actelion Pharmaceuticals Ltd Proline sulfonamide derivatives as orexin receptor antagonists
JP5847830B2 (ja) 2010-11-10 2016-01-27 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ オレキシン受容体拮抗薬として有用なラクタム誘導体
US9303023B2 (en) 2011-02-18 2016-04-05 Actelion Pharmaceuticals Ltd. Pyrazole and imidazole derivatives useful as orexin antagonists
TWI565703B (zh) 2011-11-08 2017-01-11 艾克泰聯製藥有限公司 ２-（１，２，３-三唑-２-基）苯甲醯胺及３-（１，２，３-三唑-２-基）吡啶醯胺衍生物
KR101995683B1 (ko) 2012-06-04 2019-07-02 이도르시아 파마슈티컬스 리미티드 벤즈이미다졸-프롤린 유도체
CA2885180C (en) 2012-10-10 2021-03-02 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
CN105051040A (zh) 2013-03-12 2015-11-11 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
UA119151C2 (uk) * 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
UA116053C2 (uk) 2013-12-04 2018-01-25 Ідорсія Фармасьютікалз Лтд Застосування похідних бензоімідазолу-проліну

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1549816A (zh) * 2001-06-28 2004-11-24 ʷ 作为阿立新受体拮抗药的n-芳酰基环胺衍生物
WO2007135527A2 (en) * 2006-05-23 2007-11-29 Pfizer Products Inc. Benzimidazolyl compounds
CN102325770A (zh) * 2008-12-23 2012-01-18 葛兰素集团有限公司 用作食欲肽拮抗剂的哌啶衍生物

Also Published As

Publication number Publication date
US9914720B2 (en) 2018-03-13
DK3077389T3 (da) 2017-11-13
NZ721438A (en) 2021-12-24
BR112016012628A8 (pt) 2017-12-26
LT3077389T (lt) 2017-12-11
TW201605838A (zh) 2016-02-16
PH12016500988A1 (en) 2016-06-20
ES2651475T3 (es) 2018-01-26
AU2014358742A1 (en) 2016-07-07
PT3077389T (pt) 2017-12-15
KR20160092015A (ko) 2016-08-03
WO2015083070A1 (en) 2015-06-11
ZA201604499B (en) 2019-04-24
HRP20171773T1 (hr) 2017-12-29
BR112016012628A2 (enExample) 2017-08-22
CA2929423A1 (en) 2015-06-11
KR102361418B1 (ko) 2022-02-09
CY1119695T1 (el) 2018-04-04
EP3077389A1 (en) 2016-10-12
MA39163A1 (fr) 2017-11-30
UA119549C2 (uk) 2019-07-10
NO3077389T3 (enExample) 2018-02-10
CN105793257A (zh) 2016-07-20
AU2014358742B2 (en) 2019-02-07
IL245923A0 (en) 2016-08-02
PL3077389T3 (pl) 2018-03-30
MX364208B (es) 2019-04-16
MY179862A (en) 2020-11-18
HUE035731T2 (hu) 2018-05-28
SA516371231B1 (ar) 2018-02-20
SI3077389T1 (en) 2018-01-31
EP3077389B1 (en) 2017-09-13
CA2929423C (en) 2021-12-07
MX2016007215A (es) 2016-09-07
IL245923B (en) 2019-09-26
PH12016500988B1 (en) 2016-06-20
HK1225731B (en) 2017-09-15
JP2016539136A (ja) 2016-12-15
US20160368901A1 (en) 2016-12-22
TWI664177B (zh) 2019-07-01
MA39163B1 (fr) 2018-09-28
JP6496733B2 (ja) 2019-04-03
CL2016001342A1 (es) 2016-11-18
EA201600435A1 (ru) 2016-11-30
EA030137B1 (ru) 2018-06-29

Similar Documents

Publication Publication Date Title
CN105793257B (zh) 苯并咪唑环化合物的晶形及其用途
US10023560B2 (en) Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
HK1225731A1 (en) Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
HK1225736A1 (en) Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
WO2020007977A1 (en) 7-trifluoromethyl-[1,4]diazepan derivatives
WO2020007964A1 (en) 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
BR112016012625B1 (pt) Forma cristalina de cloridrato ou hidrocloreto do composto (s)-(2-(6- cloro-7-metil-1 h-benzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3- triazol-2-il)fenil)metanona, composição farmacêutica, e, uso da forma cristalina de hidrocloreto de (s)-(2-(6-cloro-7- metil-1h-benzo[d]imidazol-2-il)-2- metilpirrolidin-1-il)(5-metoxi-2-(2h-1 ,2,3-triazol-2-il)fenil)metanona
WO2020099511A1 (en) Benzimidazole-2-methyl-morpholine derivatives
BR112016012628B1 (pt) Forma cristalina de hemi-hidrato do composto (s)-(2-(6-cloro-7-metil- 1h-benzo[d]imidazol-2-il)-2- metilpirrolidin-1-il)(5-metóxi-2-(2h-1,2,3-triazol-2-il) fenil)metanona, seu uso como antagonistas dos receptores da orexina, e, composição farmacêutica

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20171103

Address after: Swiss A Skei Weil

Applicant after: Aidu West Pharmaceutical Co. Ltd.

Address before: Swiss A Skei Weil

Applicant before: Actelion Pharmaceuticals Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant